Implantologijos ir odontologijos klinika Šypsena - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 1,182,553 | 1,527,732 | 1,305,550 | 1,667,870 | 1,985,570 | 2,297,913 | 2,285,588 | 2,573,250 |
| Profit before tax | 190,590 | 185,989 | 84,417 | 316,034 | 327,203 | 285,796 | 270,592 | 345,936 |
| Net profit | 172,157 | 158,251 | 72,295 | 274,896 | 303,861 | 259,259 | 247,186 | 296,745 |
| Equity | 180,275 | 156,764 | 79,058 | 283,366 | 318,137 | 471,513 | 530,464 | 300,150 |
| Liabilities | 221,072 | 256,090 | 213,543 | 352,501 | 533,351 | 231,723 | 452,448 | 481,446 |
| Non-current assets | 223,743 | 221,231 | 214,625 | 377,144 | 600,609 | 596,058 | 846,378 | 668,437 |
| Current assets | 196,284 | 180,455 | 76,351 | 255,856 | 236,302 | 101,174 | 124,392 | 103,081 |
| Total assets | 420,027 | 401,686 | 290,976 | 633,000 | 836,911 | 697,232 | 970,770 | 771,518 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 255,768 | 226,427 | 300,964 |
| Social insurance contributions | - | - | - | - | - | 195,872 | 175,202 | 202,413 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +44.1% | +29.2% | -14.5% | +27.8% | +19.0% | +15.7% | -0.5% | +12.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 41.0% | 39.4% | 24.8% | 43.4% | 36.3% | 37.2% | 25.5% | 38.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 95.5% | 100.9% | 91.4% | 97.0% | 95.5% | 55.0% | 46.6% | 98.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 14.6% | 10.4% | 5.5% | 16.5% | 15.3% | 11.3% | 10.8% | 11.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 16.1% | 12.2% | 6.5% | 18.9% | 16.5% | 12.4% | 11.8% | 13.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.2 | 1.6 | 2.7 | 1.2 | 1.7 | 0.5 | 0.9 | 1.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 37,344 | 43,443 | 39,662 | 45,591 | 55,155 | 56,275 | 55,520 | 63,018 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Implantologijos ir odontologijos klinika Šypsena - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-04-11 | 2022-04-13 | 1033.88 |
| 2022-04-06 | 2022-04-10 | 621.14 |
Implantologijos ir odontologijos klinika Šypsena - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-04-04 | 2025-04-04 | 13594.86 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Šypsena, UAB (code 304067946) is a Private Limited Liability Company engaged in dental practice care activities. In 2025, the company generated revenue of €2.57M, up 12.6% year on year and 12.0% over two years. Net profit increased to €296.7K, while the profit margin improved to 11.5%. The 2023–2025 trajectory shows a broadly stable base in 2023 and 2024, followed by a stronger uplift in 2025. Revenue was €2.30M in 2023 and €2.29M in 2024, before rising in the latest year. Net profit moved from €259.3K in 2023 to €247.2K in 2024 and then to the latest level in 2025. At year-end 2025, total assets stood at €771.5K, equity at €300.1K and liabilities at €481.4K. The equity ratio was 38.9% and debt-to-equity 1.60. Asset turnover reached 3.34x, supported by revenue per employee of €64.3K. Return on equity was 98.9% and return on assets 38.5%, indicating strong profitability relative to the asset base and equity level.